Sood Arjun B, Kumar Gokul, Robinson Joshua
Department of Ophthalmology, Emory University, Atlanta, GA, USA.
Emory Eye Center, Atlanta, GA, USA.
J Ophthalmic Inflamm Infect. 2016 Dec;6(1):26. doi: 10.1186/s12348-016-0095-y. Epub 2016 Jul 20.
The purpose of this study is to report a case of bilateral acute retinal necrosis in a patient with multiple sclerosis treated with natalizumab.
This study is a case report and literature review.
A 34-year-old Caucasian female with multiple sclerosis presented with 1 week of blurry vision in both eyes during treatment with natalizumab. Clinical examination revealed bilateral acute retinal necrosis. The patient was treated with systemic intravenous acyclovir and intravitreal injections foscarnet and ganciclovir. Natalizumab therapy was also discontinued.
Natalizumab is a potent immunosuppressive agent used in relapsing remitting multiple sclerosis and Crohn's disease. The use of this medication is commonly associated with opportunistic infections in the CNS. In rare cases, ocular opportunistic infections may occur and can lead to significant visual impairment and blindness. Neurologists and ophthalmologists should be aware of this potential complication.
本研究旨在报告1例接受那他珠单抗治疗的多发性硬化症患者发生双侧急性视网膜坏死的病例。
本研究为病例报告及文献综述。
1例34岁患有多发性硬化症的白人女性在接受那他珠单抗治疗期间出现双眼视力模糊1周。临床检查发现双侧急性视网膜坏死。患者接受了全身静脉注射阿昔洛韦以及玻璃体内注射膦甲酸钠和更昔洛韦治疗。那他珠单抗治疗也被停用。
那他珠单抗是一种用于复发缓解型多发性硬化症和克罗恩病的强效免疫抑制剂。使用这种药物通常会引发中枢神经系统的机会性感染。在罕见情况下，可能会发生眼部机会性感染，并可能导致严重的视力损害和失明。神经科医生和眼科医生应意识到这种潜在并发症。
